2 results
Approved WMORecruiting
The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease. Secundary endpoints address the effects of this therapy on bone…
Approved WMORecruiting
Phase 1Primary Objective• To determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumorPhase 2Primary Objective• To evaluate the ORR of NVL-520 at the RP2D in patients with…